Literature DB >> 8656002

Effect of interferon-gamma in experimental Cryptosporidium parvum infection.

J E Rehg1.   

Abstract

The activity of recombinant murine interferon-gamma (IFN-gamma) against infection by Cryptosporidium parvum was evaluated in immunosuppressed rats. Daily intraperitoneal doses of at least 125,000 U/kg significantly (P < .05) reduced the intensity of subsequent ileal infection. In addition, daily administration of 500,000 U/kg significantly (P < .05) inhibited colonization of the biliary tract. When administered for 11 days to rats with established C. parvum infection, IFN-gamma significantly (P < .05) reduced the number of parasites in the small intestine, but this treatment was ineffective against infection of the biliary tract and large intestine. Although the parasite loads in the common bile duct and large intestine were not significantly reduced, there were fewer cases of infection among the treated rats than in the control group. The data suggest that treatment with IFN-gamma may limit cryptosporidiosis of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656002     DOI: 10.1093/infdis/174.1.229

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Reactive nitrogen and oxygen species ameliorate experimental cryptosporidiosis in the neonatal BALB/c mouse model.

Authors:  G J Leitch; Q He
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Heterozygous deletion of ATG5 in Apc(Min/+) mice promotes intestinal adenoma growth and enhances the antitumor efficacy of interferon-gamma.

Authors:  Lu Wang; Yan Wang; Yuyin Lu; Qianyun Zhang; Xianjun Qu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Cryptosporidium parvum-specific mucosal immune response in C57BL/6 neonatal and gamma interferon-deficient mice: role of tumor necrosis factor alpha in protection.

Authors:  S Lacroix; R Mancassola; M Naciri; F Laurent
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Cryptosporidium parvum isolate-dependent postinfectious jejunal hypersensitivity and mast cell accumulation in an immunocompetent rat model.

Authors:  Samira Khaldi; Gilles Gargala; Laetitia Le Goff; Simon Parey; Arnaud Francois; Jean Fioramonti; Jean-Jacques Ballet; Jean-Paul Dupont; Philippe Ducrotté; Loïc Favennec
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

6.  Infection of immunocompetent mice with acid-water-pretreated Cryptosporidium parvum results in weight loss, and intestinal (structural and physiological) alterations.

Authors:  Armandina Garza; Alejandro Castellanos-Gonzalez; Alejandro Castenallos-Gonzalez; Jeffrey Griffiths; Prema Robinson
Journal:  Parasitol Res       Date:  2007-11-28       Impact factor: 2.289

7.  Colorectal cancer and Cryptosporidium spp. infection.

Authors:  Violetta Sulżyc-Bielicka; Lidia Kołodziejczyk; Sylwia Jaczewska; Dariusz Bielicki; Krzysztof Safranow; Paweł Bielicki; Józef Kładny; Wojciech Rogowski
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.